Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster lunch

1340 - m-Calpain, A New Therapeutic Target of Triple Negative Breast Cancer (556P)

Date

18 Nov 2017

Session

Poster lunch

Presenters

Kyung-Hwa JEON

Citation

Annals of Oncology (2017) 28 (suppl_10): x173-x176. 10.1093/annonc/mdx679

Authors

K. JEON, Y. Kwon

Author affiliations

  • College Of Pharmacy, Ewha Womans University-, 3760 - Seoul/KR
More

Resources

Abstract 1340

Background

Breast cancer is highly ranked as one of the most common cause of cancer death. Although Triple Negative Breast Cancer (TNBC) is not the major subtype of breast cancer in population, it is responsible for a disproportionate share of mortality with higher grade tumors and higher rates of distant recurrence. Because most of the TNBC patients represent resistance to conventional chemotherapies, new approaches are urgently needed to improve therapeutic outcome in TNBC treatment. Calpain, a family of calcium-dependent cysteine proteases, has a wide range of cellular functions related to cancer, including functions in apoptosis, hypoxia, proliferation, migration and invasion. In this study, we aimed to identify the role of m-calpain in TNBC and to evaluate m-calpain as a novel target for TNBC therapeutics.

Methods

The correlation between m-calpain expression and clinical outcome in TNBC was investigated using database analysis. m-Calpain knock-down cellular model was constructed using MDA-MB-231 cell line. Proliferation rate and migration capacity of m-calpain KD cells were compared to those of empty vector transduced cells using WST assay and wound healing assay. EMT related gene expression was investigated using immunoblot, immunofluorescence, and quantitative RT-PCR. Subcellular localization of HIF-1α was confirmed using immunofluorescence assay. ChIP assay was conducted to analyze the interaction of HIF-1α with Twist promoter. Anoikis sensitivity in m-calpain KD cells was investigated using WST assay, Annexin V/PI double staining, and immunoblotting analysis.

Results

m-Calpain expression was closely correlated with survival of TNBC patients in database analysis. m-Calpain silenced TNBC cells showed phenotypical changes representing inhibition of EMT signaling. Among the EMT related transcription factors, only twist expression was inhibited by m-calpain downregulation. The reduction of twist expression was due to the alteration of subcellular localization of HIF-1α.

Conclusions

The results indicate that m-calpain could play an important role in EMT process via HIF-1α translocation, followed by Twist expression. m-Calpain might serve as a novel target for therapeutic strategies of TNBC patients.

Clinical trial identification

Legal entity responsible for the study

Ewha Womans University

Funding

Basic Science Research Program through the National Research Foundation of Korea(NRF) funded by the Ministry of Education (NRF-2017R1D1A1B03027846) Brain Korea 21 plus funded by the Ministry of Education

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.